Triple-negative breast cancer accounts for approximately 15% of all breast cancer cases. Patients with this subtype typically have poorer outcomes compared to other breast cancers, suggesting the need ...

Among the hurdles to treating brain cancer is the fact that glioblastoma multiforme (GBM) cells burrow into brain tissue, which makes them difficult to wipe out with conventional treatments like ...

Californian immuno-oncology biotech CG Oncology has reeled in a $47 million series D—and, surely, an IPO isn’t far behind—as it looks to phase 3 trials. The funding was led by new investor Kissei ...

The oncolytic virus, MEM-288 will be studied in combination with Opdivo for patients with non-small cell lung cancer that progressed on standard therapy. The next phase of a clinical trial will ...

Cutaneous squamous cell carcinoma that does not respond to treatment with an immunotherapy called a checkpoint inhibitor has no FDA-approved therapeutic alternatives. Replimune’s lead program, an ...

One type of cancer immunotherapy, called oncolytic viral therapy, works by infecting cancer cells with a specific virus. Some oncolytic viruses occur naturally, while others result from specialized ...

A multi-institutional team of Chinese microbiologists and pharmacologists has developed a novel way to fight cancerous tumors. Called ONCOTECH, it combines oncolytic virotherapy and adoptive T cell ...

Equipping cancer-infecting, or oncolytic, viruses with tumor-inhibiting genetic cargo stimulates the immune system and helps immunotherapy to shrink or completely clear aggressive tumors in mice, ...

Please provide your email address to receive an email when new articles are posted on . Use of a modified herpesvirus with and without radiation showed promising efficacy and safety for the treatment ...

DUARTE, Calif.--(BUSINESS WIRE)--City of Hope, a world-renowned research and treatment organization for cancer, diabetes and other life-threatening diseases, today announced the opening of a ...